Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
Milton Packer(Baylor University Medical Center), Cordula Zeller(Inserm), Inder S. Anand(University of Minnesota), John R. Teerlink(University of Glasgow), Markus Haass(St. Hedwig-Krankenhaus), Javed Butler(Jackson Memorial Hospital), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(London School of Hygiene & Tropical Medicine), Steen Pehrson(Copenhagen University Hospital), Sven Schnaidt(Inserm), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Peter E. Carson(Inserm), Janet Schnee(Boehringer Ingelheim (United States)), Wolfram Doehner(Deutsches Herzzentrum der Charité), Alan B. Miller(Touro University California), João Pedro Ferreira(Inserm), Stefan D. Anker(Bayer (Germany)), Michel Komajda(Hôpital Saint Joseph)
Cited by 343
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k